Table 3 Demographic characteristics of COVID arm following mRNA-1273 Moderna vaccine
From: COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review
Characteristic | Participants N.o (%) |
|---|---|
Total | 1129 (100) |
Sexa | |
Female | 745 (65.9) |
Male | 348 (34.1) |
Patient age, meana | 43.8 |
Past dermatologic history | |
None | 12 (1.0) |
Psoriasis | 1 (0.0) |
Atopic dermatitis | 2 (0.1) |
Urticaria | 6 (0.5) |
Unknown | 1111 (98.4) |
Past medical history | |
None | 24 (2.1) |
Atopic allergy | 30 (2.6) |
Atrial fibrillation | 1 (0.0) |
Hypothyroidism | 1 (0.0) |
Morbid obesity | 1 (0.0) |
Unknown | 1074 (95.1) |
Medication | |
None | 41 (3.6) |
Topical corticosteroid | 23 (2.0) |
Emollients | 2 (0.1) |
Oral corticosteroid | 3 (0.2) |
Oral antihistamine | 23 (2.0) |
NSAIDs | 2 (0.1) |
Antibiotics | 4 (0.3) |
Unknown | 1047 (92.7) |
Reaction to dose | |
First dose | 997 (88.3) |
Second dose | 66 (5.8) |
Recurrent | 35 (3.1) |